2022 Add Health Users Conference

Add Health Wave V Biological Data and Vital Events

Tuesday July 12, 2022

10:15-11:45 AM

Eric A. Whitsel, MD MPH
Department of Epidemiology, Gillings School of Global Public Health
Department of Medicine, School of Medicine
University of North Carolina at Chapel Hill

eric whitsel@med.unc.edu





Add Health Wave V

- Biological Data
- Vital Events





Wave V Biological Data - Choice

- Conditions prevalent among young-to-middle aged U.S. adults
- Processes by which they are associated with future health
- Measures characterizing those processes
- Feasibility of field collection across U.S.
- Availability of data across waves
- Reliability & validity of results





Wave V Biological Data – Domains

- Cardiovascular
- Anthropometric
- Metabolic
- Inflammatory
- Renal
- Omic
- Pharmacologic
- Other





Biological Data Domains and Measures

Cardiovascular SBP [mmHg]

DBP [mmHg]

PR [beats/min]

Anthropometric Weight [kg]

Height [cm]

Waist Circumference [cm]

Arm Circumference [cm]

Metabolic Hb_{A1c} [%]

Glucose [mg/dl]

TC [mg/dL]

HDL-C [mg/dL]

TG [mg/dL]

Inflammatory hsCRP [mg/L]

Renal Creatinine [mg/dL]

Cystatin C [mg/L]

Omic Transcriptome

Microbiome

Epigenome

Pharmacologic Medication Use

DBP = diastolic blood pressure. Hb_{A1c} = hemoglobin A1c. HDL-C = high-density lipoprotein cholesterol. PR = pulse rate. SBP = systolic blood pressure. TC = total cholesterol. TG = triglycerides.





- Cardiovascular
 - Primary
 - systolic blood pressure (SBP)
 - diastolic blood pressure (DBP)
 - pulse rate (PR)
 - Secondary
 - pulse pressure (PP = SBP DBP)
 - mean arterial pressure (MAP = $[SBP + 2 \times DBP] \div 3$)





Wave V Biological Data - Classification

- Cardiovascular
 - SBP/DBP according to JNC 7 guidelines*

< 120/80 mm Hg Normal

120-139/80-89 mm Hg Pre-Hypertension

140-159/90-99 mm Hg Stage 1 Hypertension

≥ 160/100 mm Hg Stage 2 Hypertension


SBP/DBP according to ACC/AHA guidelines†

< 120/80 mm Hg

120-129/<80 mm Hg Elevated

130-139/80-89 mm Hg Stage 1 Hypertension

≥ 140/90 mm Hg Stage 2 Hypertension







- Anthropometric
 - Primary
 - weight
 - height
 - waist circumference (waist)
 - arm circumference (arm)
 - Secondary
 - body mass index (BMI = weight in kg / height in m²)





Wave V Biological Data - Classification

Anthropometric

Waist according to NHLBI Evidence Report*

 \leq 88 (102) cm in \bigcirc (\circlearrowleft) Lower Risk

> 88 (102) cm in \bigcirc (\bigcirc) High Risk

BMI according to NHLBI Evidence Report*

< 18.5 kg/m² Underweight

18.5-24.9 kg/m² Normal

25.0-25.9 kg/m² Overweight

30.0-34.9 kg/m² Obesity, Stage I

35.0-39.9 kg/m² Obesity, Stage II

≥ 40.0 kg/m² Obesity, Stage III





- Metabolic, lipids*
 - Primary
 - total cholesterol (TC)
 - high density lipoprotein cholesterol (HDL-C)
 - triglycerides (TG)
 - Secondary
 - low density lipoprotein cholesterol (LDL-C = TC HDL-C TG ÷ 5)†
 - TC:HDL-C ratio (= TC / HDL-C)
 - non-HDL-C (= TC HDL-C)





Wave V Biological Data - Classification

Metabolic, lipids*



According to NCEP ATP III guidelines†

_	· · · · · · · · · · · · · · · · · · ·		
•	TC (mg/dl)	< 200	desirable
		200-239	borderline high
		≥ 240	high
•	HDL-C (mg/dl)	< 40	low
		≥ 60	high
•	LDL-C (mg/dl)	< 100	optimal
		100-129	near optimal
		130-159	borderline high
		160-189	high
		≥ 190	very high
•	TG‡ (mg/dl)	< 150	normal
	, , ,	150-199	borderline high
		200-499	high
		≥ 500	very high
		_ 000	

According to AHA/ACC guidelines

	_	-	
•	LDL-C (mg/dl)	160-189	moderate
		≥ 190	severe hypercholesterolemia
•	TG‡ (mg/dl)	175-499	moderate
	_	≥500	severe hypertriglyceridemia





- Metabolic, glucose homeostasis*
 - glucose
 - glycosylated hemoglobin (HbA1c)





Wave V Biological Data - Classification

- Metabolic, glucose homeostasis*
 - According to ADA guidelines†
 - fasting glucose (mg/dl)

```
≤99 normal
```

100-125 impaired

≥ 126 diabetes

non-fasting glucose (mg/dl)

```
≥ 200 diabetes
```

• HbA1c (%)

5.7-6.4 increased risk for diabetes

≥ 6.5 diabetes





- Inflammatory
 - high sensitivity C-reactive protein (hsCRP)





Wave V Biological Data - Classification

Inflammatory

hsCRP according to CDC / AHA guidelines*

< 1 mg/L low

1-3 mg/L average

> 3 mg/L high

> 10 mg/L must trigger searches for factors

capable of confounding hsCRP-

based risk estimates







- Renal
 - Primary
 - creatinine
 - cystatin c
 - Secondary
 - estimated glomerular filtration rate (eGFR in ml/min/1.73 m²)* = 141 × min(Scr/ κ , 1) α × max(Scr/ κ , 1) α × 0.993^{Age} [× 1.018 if α)] [× 1.159 if black], where:

```
Scr = serum creatinine

\kappa = 0.7 (9) \text{ or } 0.9 (3)

\alpha = -0.329 (9) \text{ or } -0.411 (3)
```

- analogous formulas for Scys & Scr-cys
- newer NKF/ASN-endorsed equations include both, omit race & are most accurate





Wave V Biological Data - Classification

Renal

eGFR according to KDIGO guidelines*

≥90 ml/min/1.73 m² Normal or high (G1)

60-89 Mildly decreased (G2)*

45-59 Mildly to moderately decreased (G3a)

30-44 Moderately to severely decreased (G3b)

15-29 Severely decreased (G4)

<15 Kidney failure (G5)





- Pharmacologic
 - prescription medications
 - select over-the-counter medications (salicylates & NSAIDS)





Wave V Biological Data - Classification

- Pharmacologic
 - prescriptions according to Multum Lexicon Plus®
 - example therapeutic classes
 - antihypertensives
 - antihyperlipidemics
 - antidiabetics
 - anti-inflammatories
 - narcotics
 - antidepressants
 - antipsychotics
 - anxiolytics
 - anticonvulsants







NEW!


Other

- Additional Inflammatory/Immune
 - IL-1B, 6, 8 & 10
 - Tumor Necrosis Factor (TNF-α)
 - Cytomegalovirus (CMV)
- Hepatic
 - Aspartate Aminotransferase (AST)
 - Alanine Aminotransferase (ALT)
 - AST:ALT Ratio
- Neurodegeneration
 - Neurofilament Light Chain (NfL)
 - Tau






- Scheduling
- Preparation
- Interview
- Examination
- Medication Inventory
- Phlebotomy
- Processing
- Data Upload







Scheduling







Scheduling

	Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
Morning	√	√ *	√ *	√ *	√ *	✓	×
Afternoon	✓	√ *	√ *	√ *	✓	✓	×
Evening	√	✓	√	✓	×	×	×

^{√*} Preferred – if able to meet same day FedEx cutoff

X Not Acceptable





[√] Acceptable – if able to meet next day FedEx cutoff

Preparation

Home visit equipment and supply list

- Photo ID Badge
- · Samsung Galaxy 4 Tablet with power cord
- · Microlife blood pressure unit with medium and large cuff
- Spare batteries for blood pressure unit (4 X AA)
- · SECA circumferential tape measure
- · Metal tape measure
- · Carpenter's square
- · Health-o-Meter weight scale
- Spare batteries for Health-o-Meter scale (2 X CR2032)
- · Cooler/ice packs for cooling samples until centrifugation
- Job Aid Documents
- Pens and Sharpies
- EMSI supplied respondent contact and information sheet
- Pre-printed Post-It notes
- Biohazard bag
- Cardiovascular Health Fact Sheet
- Respondent Fact Sheet
- Protective cover (Chux) for table top (examiner supplied)
- Sharps Container (examiner supplied)

Prepackaged home visit kit

- Vacutainer holder
- 21 gauge needle
- Nitrile gloves
- 2" x 2" gauze pad
- Bandage
- Tourniquet
- 5 or 6 Vacutainer tubes *** The 6th Vacutainer tube (6ml sodium fluoride tube) is required only if respondent's appointment information indicates it is to be collected.
- Biohazard Ziploc bag
- Alcohol prep pad
- Pipettes
- · Transport tubes
- 4 Loose Barcode Labels [for shipping manifest, paper version of questionnaire (if needed), glucose transport tube (if needed), and one extra]

 Styrofoam container
- FedEx mailing pouch




















- Interview & Examination
 - Relied on a Samsung Tablet to
 - guide interview & exam
 - record self-reported health status
 - record physical measurements
 - tailor follow-up recommendations
 - inventory / code medications
 - guide biospecimen processing & shipping
 - control data quality (range checks; double entry)
 - transmit data







- Examination
 - Cardiovascular equipment

<u>Measure</u>	Equipment	Pictures	<u>Specifications</u>
Arm	Seca 200 Circumference Tape Measure	Second Second	200 cm maximum 2-sided cm scaling 1 mm graduations fiberglass tape Add Health-validated* plastic case automatic roll-up end-peg positioner 90 x 25 x 65 mm 50 g < \$13





Examination

Cardiovascular equipment


Measures	Equipment	Picture	<u>Specifications</u>
SBP	MicroLife		30-280/40-200 BP/PR range
DBP	3MC1-PC_IB		1-unit graduations
PR	Oscillometric BP	See Microlife	198 measure recall ± 3 mmHg accuracy
	Monitor	microm aggre	± 5 beat pulse accuracy
		START W	BHS-approved
			Add Health-validated*
			4 "AA" battery-powered
			w/ AC adapter + USB cable 2 cuffs (24-41 cm)
			160 x 140 x 98 mm
			735 g (w/ batteries)
			< \$65





- Examination
 - Cardiovascular protocol*
 - trained, certified staff
 - resting, seated respondents
 - arm @ level of heart
 - cuff matched to arm circumference
 - measured SBP, DBP & PR
 - - 3x @ 30 sec intervals
 - - double entered
 - automatically averaged over last 2
 - provide results, follow-up recs









- Examination
 - Anthropometric equipment

<u>Equipment</u>	<u> Pictures</u>	<u>Specifications</u>
Carpenter's Square		portable light weight inexpensive true 90° angle
Tape Measure	000.456.789	10 ft steel tape
Post-it Notes	Measure to top Height:cm Weight:kg	adherent pre-labeled
	Carpenter's Square Tape Measure Post-it	Carpenter's Square Tape Measure Post-it Notes Measure to top Height





- Examination
 - Anthropometric equipment

<u>Measure</u>	Equipment	Pictures	<u>Specifications</u>
Weight	Health-O-Meter		4-point load cell
	844KL High	Kenna	digital display in lb / kg
	Capacity		440 lb maximum
	Digital		0.1 lb graduations
	Scale	-	Add Health-validated*
			long life Li ⁺⁺ battery
		Measure to top	low battery warning
		Height: cm	1-year warranty
		Heighton	12.6 x 12.6 in
		Weight:kg	4.5 lb
		Waist:cm	< \$70





Examination


Anthropometric equipment

<u>Measure</u>	Equipment	Pictures	<u>Specifications</u>
Arm	Seca 200 Circumference Tape Measure	Second Second	200 cm maximum 2-sided cm scaling 1 mm graduations fiberglass tape Add Health-validated* plastic case automatic roll-up end-peg positioner 90 x 25 x 65 mm 50 g < \$13





- Examination
 - Anthropometric protocol
 - trained, certified staff
 - dressed, unshoed respondents
 - standing on uncarpeted floor
 - measured
 - height to nearest 0.5 cm
 - weight to nearest 0.1 kg
 - waist to nearest 0.5 cm
 - @ superior border of iliac crest
 - @ end expiration
 - horizontal to floor
 - hair/shoe height to nearest 0.5 cm, as needed












- Medication Inventory
 - Protocol

Start Inventory

Enter Meds

Enter Sources










- Phlebotomy & Processing
 - Protocol
 - trained, certified phlebotomists
 - fasting (ideally) respondents
 - draw blood
 - centrifuge
 - package
 - ship
 - assay @ LCBR
 - return results





















Wave V Biological Data - Key Results

Overall

• Surveyed 12,300

• Consented 8,379 (68%)


• Examined 5,381 (64%)





Wave V Biological Data - Key Results

• Overall (unweighted)




Variable	Mean	SD	P25	P50	P75
Visits / Day	8.1	6.7	3.0	6.0	12.0
Start Time (0-23)	11.1	3.2	8.9	10.1	12.7
Duration (min)	37.8	18.2	28.0	35.0	44.3
Fasting (hr)	9.5	5.9	3.6	11.2	13.7





Cardiovascular

(unweighted)



Variable	Mean	SD	P25	P50	P75	P90	P95
SBP (mm Hg)	123	15	113	122	131	141	148
DBP (mm Hg)	79	11	72	79	86	93	98
PR (b/min)	75	12	67	74	83	91	95


49% ≥ 130/80 (Stage 1) 19% ≥ 140/90 (Stage 2)

9% ≤ 60 (Bradycardia) 3% ≥ 100 (Tachycardia)





• Anthropometric (unweighted)



Variable	Mean	SD	P25	P50	P75	P90	P95
Waist (cm)	97.7	19.0	84.0	96.0	109.0	123.0	133.0
BMI (kg/m ²)	30.7	7.8	24.9	29.2	34.7	41.2	45.9


51% > 88 or 102 (High Risk) 75% > 25 (Overweight or Obese)





Metabolic

(unweighted)



Variable	Mean	SD	P25	P50	P75	P90	P 95	_
Glucose (mg/dl)	95	36	82	89	97	110	132	•
HbA1c (%)	5.4	0.9	5.0	5.2	5.4	5.7	6.3	ì
TC (mg/dl)	181	36	156	177	202	227	242	
HDL-C (mg/dl)	50	15	39	47	58	70	78	
LDL-C (mg/dl)	106	32	84	103	125	146	160	ı
TG (mg/dl)	129	95	71	102	156	237	298	ì


 $3.9\% \ge 126 \text{ or } 200 \text{ (Diabetes)}$ $4.6\% \ge 6.5 \text{ (Diabetes)}$


5.1% ≥ 160 (Hypercholesterolemia) 20% ≥ 175 (Hypertriglyceridemia)






Inflammatory & Renal







Variable	Mean	SD	P25	P50	P75	P90	P95	_	
hsCRP (mg/L)	4.1	6.3	8.0	1.8	4.7	9.8	16	_	20% > 3 (High)
Creatinine (mg/dl)	8.0	0.4	0.7	8.0	0.9	1.1	1.2		
	Mean	SD	P 5	P10	P25	P50	P 75		
GFR (ml/min/1.73m ²)	104	16	77	83	94	106	113	_	19% < 90 (Decreased) 0.7% < 60 (CKD or ESKD)





- Pharmacologic
 - Prescription medication use, by therapeutic class

```
• antihypertensives 12.1%
```

• antihyperlipidemics 3.8%

• antidiabetics 4.8%

• NSAID/salicylate 5.5%

.

•

•





- Other
 - Inflammatory/Immune
 - Hepatic
 - Neurodegeneration

Pending!





- Threats
 - poorly trained or monitored staff
 - departures from standardized protocol
 - use of heterogeneous, untested equipment
 - reliance on manual processes
 - missing data
 - measurement error
 - trend / cyclicity
 - digit preference
 - inaccuracy
 - unreliability





Control

- uniformly train & monitor staff
- follow standardized protocol
- use standard, tested equipment
- automate processes
- track / reduce missing data
- track / reduce measurement error
 - trend / cyclicity
 - digit preference
 - inaccuracy
 - unreliability





Reliability

Race / Ethnicity	Sex	Intra- Individual Variation Sub-Study*
White	Male	12
	Female	12
Black	Male	12
	Female	12
Hispanic	Male	12
	Female	12
Other	Male	12
	Female	12
Total		96

^{*}Involved examining participants 2x, 1-3 weeks apart, on ~ same day of week @ same time of day.





Reliability

MEASURE	N	ICC	(95% CI)
SBP23	112	0.72	(0.64,0.81)
DBP23	112	0.71	(0.62,0.80)
PR23	112	0.72	(0.63,0.81)
Arm	112	0.86	(0.82,0.91)
Height	110	0.95	(0.93,0.97)
Weight	110	1	(1.00,1.00)
Waist	109	0.96	(0.94,0.97)
ВМІ	110	0.98	(0.98,0.99)
GLUCOSE	103	0.94	(0.91,0.96)
HBA1C	101	0.99	(0.99,0.99)
TG	103	0.63	(0.51,0.74)
TC	103	0.88	(0.84,0.92)
HDL-C	103	0.95	(0.94,0.97)
LDL-C	103	0.86	(0.81,0.91)
HSCRP	94	0.82	(0.75,0.89)
CREATININE	103	0.93	(0.91,0.96)
CYSTATIN-C	103	0.86	(0.81,0.91)
GFR	103	0.89	(0.85,0.93)

^{*}The corresponding agreement (95% CI) between therapeutic classified prescription medications = 85% (79%-92%), kappa coefficient (95% CI) = 0.82 (0.71-0.93).





Wave V Vital Events





Wave V Vital Events


- Rationale
- NEW!
- Surveillance
 - Tracing, Screening & Matching
 - Investigation & Abstraction
 - Review, Classification & Adjudication
- Results
- Quality





Wave V Vital Events - Rationale

Risk Factor Distributions @ Wave IV








Wave V Vital Events - Goal

- To establish a scalable infrastructure for surveillance of chronic disease events, initially by ascertaining decedents
- To anticipate the epidemiologic transition to rapid increases in chronic disease morbidity and mortality with age
- To do so under "The Biology of Chronic Disease Emergence and Medical Outcomes Surveillance" (Wave V Project 5096; P01-HD031921)






Wave V Vital Events - Surveillance



Tracing, Screening & Matching




640 of 641 Decedents Matched 1:1

NDI 1994-2020 & 2021 (preliminary)





Tracing, Screening & Matching






Source: NDI, 1995- 2021



Tracing, Screening & Matching

Temporal Distribution of Deaths







Tracing, Screening & Matching

 Demographic Distribution
 of Deaths

Characteristic		Mean (Range) or %
Age, years		32.3 (14-46)
Female		37%
Race/ethnicity	EA	53%
	AA	25%
	HL	12%
	A/PI	5%
	AI/AN	3%
	O/M	2%

AA = African American. Al/AN = American Indian/Alaskan Native.


A/PI = Asian/Pacific Islander. EA = European American.

HL = Hispanic/Latino. O/M = Other/Multiple.






Investigation & Abstraction



2 Investigate & Abstract


Executed Add Health-State* Agreements to Provide Death Certificates










- Investigation & Abstraction
 - Abstracted Records













- Investigation & Abstraction
 - Quality Control

Abstraction Form	Agreement	Kappa
Obituary	0.86 (0.84-0.89)	0.83 (0.80-0.86)
Death Certificate	0.93 (0.92-0.95)	0.92 (0.90-0.94)
CME Autopsy Report	0.90 (0.87-0.93)	0.86 (0.83-0.90)
Hospital Record*	0.94 (0.92-0.95)	0.91 (0.89-0.93)

Among a random sample of 28 decedents and an oversample of 28 hospitalized decedents enriched 3:1 for cardiovascular disease. CME = Coroner / Medical Examiner. Kappa = prevalence- and bias-adjusted kappa coefficient. *Mean, biomarker-specific intra-class correlation coefficient (95% confidence interval) = 0.96 (0.95-0.98).

Circulation 2022:145(S11);P154.





Investigation & Abstraction

Manner & Underlying Cause of Death

Manner of Death*	%
Accidental	41.6
Natural	33.4
Suicide	13.2
Homicide	10.1
Undetermined	1.6

^{*}From death certificate


Underlying Cause of Death [†]	<u> </u>
Motor Vehicle Accident	16.1
Cardiovascular Disease	15.1
Accidental Drug Intoxication	13.9
Suicide	11.1
Cancer	9.4
Homicide	7.2
Other Natural Cause	7.0
Infectious Disease	3.7
Other Accident	3.3
Unknown/Undetermined	3.3
Respiratory Disease	2.5
Digestive Disease	2.3
COVID-19	2.2
45 105 0 1 01511	

†From ICD Codes (NDI)





Review, Classification & Adjudication



In Progress!





Wave V Biological Data & Vital Events

Summary

- Wave V biological data, weights, documentation & biospecimens available
 - sample size ~ 5,400
 - quality high
 - other inflammatory/immune, hepatic & neurodegeneration biomarkers pending
- Vital events available
 - decedents (1994-2021) = 641
 - cumulative mortality = 3.1%
 - natural causes account for ~ 1/3
 - quality high
 - physician review, classification & adjudication ongoing
- Stay tuned re dissemination! (https://addhealth.cpc.unc.edu/documentation/user-guides)
- Consider ancillary studies! (https://addhealth-ancillary.cpc.unc.edu/home)







Acknowledgements

Wave VI of Add Health is supported by two grants from the National Institute on Aging (1U01AG071448, principal investigator Robert A. Hummer, and 1U01AG071450, principal investigators Allison E. Aiello and Robert A. Hummer) to the University of North Carolina at Chapel Hill. Co-funding for Wave VI is being provided by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institute on Minority Health and Health Disparities, the National Institute on Drug Abuse, the NIH Office of Behavioral and Social Science Research, and the NIH Office of Disease Prevention. Waves I-V data are from the Add Health Program Project, grant P01 HD31921 (PI: Kathleen Mullan Harris) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, with cooperative funding from 23 other federal agencies and foundations. The content of this presentation is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health or the University of North Carolina at Chapel Hill.

Add Health was originally designed by J. Richard Udry, Peter S. Bearman, and Kathleen Mullan Harris at the University of North Carolina at Chapel Hill. Add Health is currently directed by Robert A. Hummer; it was previously directed by Kathleen Mullan Harris (2004-2021) and J. Richard Udry (1994-2004).

Information on obtaining Add Health data is available on the project website (https://addhealth.cpc.unc.edu).



